Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients

A Registry-Based Report

Ivan Zahradka, MD*; Vojtech Petr, MD*; Istvan Modos, MSc, PhD; Maria Magicova, MD; Ladislav Dusek, PhD; and Ondrej Viklicky, MD, PhD

Background: The real-world protection provided by SARS-CoV-2 messenger RNA (mRNA) vaccines to kidney transplant recipients (KTRs) remains uncertain.

Objective: To study the association between mRNA vaccination and SARS-CoV-2 infection rate in KTRs.

Design: Retrospective observational cohort study.

Setting: The Czech Republic (17 February to 16 May 2021).

Patients: 2101 KTRs followed in the Department of Nephrology at the Institute for Clinical and Experimental Medicine.

Measurements: Positive result for SARS-CoV-2 on polymerase chain reaction test and vaccination status of KTRs.

Results: The incidence rate in the vaccinated group was 0.474 per 1000 person-days (33 cases in 69,672 days at risk). The incidence rate in the unvaccinated group was 1.370 per 1000 person-days (79 cases in 57,658 days at risk). The unadjusted incidence rate ratio (IRR; incidence rate of vaccinated/incidence rate of unvaccinated) for KTRs was 0.346 (95% CI, 0.227 to 0.514). The multivariable adjusted IRR for KTRs was 0.544 (CI, 0.324 to 0.876).

Limitation: Retrospective observational design, uneven follow-up of patient groups, and different exposition to SARS-CoV-2 stemming from strong temporal trends and differences in clinical and probably behavioral characteristics.

Conclusion: Vaccination of KTRs is associated with lower risk for SARS-CoV-2 infection.

Primary Funding Source: The Ministry of Health of the Czech Republic.

© 2022 American College of Physicians

Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients

Kidney transplant recipients (KTRs) are considered particularly vulnerable to SARS-CoV-2 infection, as higher rates of inpatient mortality, far exceeding those seen in the general population, have been reported (1–4). The SARS-CoV-2 messenger RNA (mRNA) vaccines have shown high clinical efficacy in preventing COVID-19 in the immunocompetent population (5, 6). However, impaired humoral and cellular responses to mRNA vaccines have recently been reported in KTRs (7–9). The assumption of an impaired vaccine response in KTRs is further supported by the well-known fact of a decreased immune response to influenza or pneumococcal vaccines in the transplant population (10–12). However, data about the effectiveness of SARS-CoV-2 vaccines are conflicting (13–15), and to what extent the 2 doses of an mRNA vaccine protect KTRs from COVID-19 is unclear. Furthermore, a third booster dose of an mRNA SARS-CoV-2 vaccine has been recently tested and applied in many countries (16–18).

Because randomized controlled trials in immunocompromised populations may not be ethically feasible, registry data may provide information on the association between SARS-CoV-2 vaccines and clinical protection of KTRs. Thus, to evaluate the association between SARS-CoV-2 mRNA vaccines and infection rates in KTRs, we did a retrospective registry-based cohort study of 2101 KTRs followed at our center.

Outcomes and Follow-up

The primary outcome of the study was the incidence of SARS-CoV-2 infection, defined as a positive result for SARS-CoV-2 on a polymerase chain reaction (PCR) test, among fully vaccinated KTRs compared with unvaccinated KTRs. In addition, we analyzed COVID-19-related deaths and breakthrough infections.

The follow-up period started on 17 February and ended on 16 May 2021. The follow-up was ended on reaching the end point (PCR positivity), censoring (death or return to long-term dialysis), or on reaching the end of the study period. Study participants were divided into 2 subgroups depending on vaccination status (that is, vaccinated or unvaccinated) at the end of the follow-up.

The person-time for every participant was first counted toward the total person-days of the unvaccinated group, regardless of the latter vaccination. Those who survived without having a positive PCR test result until reaching full vaccination status (2 weeks after the second dose) were moved to the vaccinated subgroup, and their person-time started counting toward the total person-days of the vaccinated group. Therefore, vaccinated participants initiated their follow-up designated as unvaccinated, and their designation was later changed to vaccinated. This means that they contributed their follow-up time to both groups at
some point but never to both at the same time. The person-time between the administration of the first vaccine dose and reaching full vaccination status was eliminated and was therefore not counted toward total person-days of either category (vaccinated or unvaccinated).

To establish a SARS-CoV-2-naive cohort, KTRs infected before the vaccination campaign were excluded, as were patients vaccinated with non-messenger RNA vaccines. In total, 2101 KTRs were considered as the SARS-CoV-2-naive cohort. Of these, 1601 KTRs contributed at least part of their follow-up time to the unvaccinated days at risk, whereas 500 did not contribute. These were the KTRs vaccinated between 13 January and 17 February, 6 of whom did not finish vaccination and thus did not contribute to any days at risk, and 494 of whom entered the study denoted as unfinished vaccination but afterward reached full vaccination status and, therefore, contributed only toward vaccinated days at risk. A total of 246 KTRs did not finish full vaccination because they had a positive result for SARS-CoV-2 infection after the first dose ($n = 28$), they did not receive the second dose for other reasons ($n = 5$), or they received the first dose before the end of the study period but reached full vaccination status after its end ($n = 213$). Kidney transplant recipients who did not finish full vaccination contributed to the unvaccinated days at risk and were censored at the day of first vaccine dose. A total of 1509 reached full vaccination and contributed toward vaccination days at risk; of these, 33 became positive for SARS-CoV-2 during the study period. A total of 346 were unvaccinated by the end of the study period, and 79 of them became positive for SARS-CoV-2 during the study period. KTR = kidney transplant recipient; PCR = polymerase chain reaction.

Overall, 2479 KTRs with functional grafts were considered for inclusion to the study. To establish a SARS-CoV-2-naive cohort, patients with previous positive results for SARS-CoV-2 infection were excluded, as were patients vaccinated with non-messenger RNA vaccines. In total, 2101 KTRs were considered as the SARS-CoV-2-naive cohort. Of these, 1601 KTRs contributed at least part of their follow-up time to the unvaccinated days at risk, whereas 500 did not contribute. These were the KTRs vaccinated between 13 January and 17 February, 6 of whom did not finish vaccination and thus did not contribute to any days at risk, and 494 of whom entered the study denoted as unfinished vaccination but afterward reached full vaccination status and, therefore, contributed only toward vaccinated days at risk. A total of 246 KTRs did not finish full vaccination because they had a positive result for SARS-CoV-2 infection after the first dose ($n = 28$), they did not receive the second dose for other reasons ($n = 5$), or they received the first dose before the end of the study period but reached full vaccination status after its end ($n = 213$). Kidney transplant recipients who did not finish full vaccination contributed to the unvaccinated days at risk and were censored at the day of first vaccine dose. A total of 1509 reached full vaccination and contributed toward vaccination days at risk; of these, 33 became positive for SARS-CoV-2 during the study period. A total of 346 were unvaccinated by the end of the study period, and 79 of them became positive for SARS-CoV-2 during the study period. KTR = kidney transplant recipient; PCR = polymerase chain reaction.
study. Institutional review board approval is not required for anonymous retrospective observational studies under the current legislature in the Czech Republic.

**Setting and Participants**

All KTRs with functioning kidney allografts followed at our transplant center were considered for inclusion in the study. The Institute for Clinical and Experimental Medicine (IKEM) is a high-volume transplant center (21) that primarily covers geographic regions of the country's capital Prague and the regions of Central, Southern, and Northern Bohemia, accounting for about 50% of the population of the Czech Republic. To illustrate, in 2019, IKEM performed 58% of the total number of kidney transplants in the country (299 kidney transplants out of 510).

The Czech Republic is a small country with 10.7 million inhabitants with a very homogeneous structure of population and habitation. There are no significant racial minorities – 99.8% of Czech citizens are White. The population density is roughly the same around the country, with an average of 139 citizens per square kilometer.

**National Registry for Infectious Diseases and Other Sources of Data**

The National Registry for Infectious Diseases gathers all data about each PCR and antigen test done, each vaccine dose applied in the country, and all mandatory quarantine periods. Therefore, when the study was initiated, the risk for infection was high, and a large proportion of events was captured as Cohen’s d with pooled SD for continuous variables and proportion differences for binary variables. There were 33 cases of SARS-CoV-2 infection detected among vaccinated KTRs and 79 cases among unvaccinated KTRs during the study period.

The clinical characteristics of the KTRs (age at the time of positive PCR test result, sex, body mass index (BMI), retransplantation status, most recent estimated glomerular filtration rate, years from transplant, vaccination status against influenza in 2019, university or college degree, urban or rural place of residence, and maintenance immunosuppression) (Table 1) were obtained from the hospital information system of IKEM. The clinical course of COVID-19 and the outcomes were recorded by a transplantation coordinator and a physician (M.M.) for each KTR with SARS-CoV-2 infection.

**COVID-19 Setting and Baseline Risk for Infection**

The Czech Republic was severely affected by the COVID-19 pandemic, and with 155,464 cases per million at the end of June 2021, it became the fourth most heavily affected country in the world at the time. In contrast, the cumulative incidence in the United States was 101,289 per million (Figure 2) and 44,531 in neighboring Germany at the same point in time.

The study period covers the entirety of the third and most severe wave of the pandemic (Figure 2). The highest number of confirmed infections was reported on 7 January 2021, with 17,773 positive PCR tests in a single day (0.17% of the whole Czech population). In the first week of January 2021, almost 1% of the population tested positive (90,684 new cases between 3 January and 9 January 2021) (23).

Therefore, when the study was initiated, the risk for infection was high, and a large proportion of events was captured as Cohen’s d with pooled SD for continuous variables and proportion differences for binary variables. There were 33 cases of SARS-CoV-2 infection detected among vaccinated KTRs and 79 cases among unvaccinated KTRs during the study period.

**Table 1. Demographic Characteristics of the COVID-19-Naive KTRs**

| Characteristic                                      | Vaccinated (n = 1509) | Unvaccinated (n = 346) | Standardized Mean Differences (95% CI)* |
|-----------------------------------------------------|-----------------------|------------------------|---------------------------------------|
| Mean age (SD), y                                    | 61.28 (11.78)         | 54.20 (14.26)          | 0.58 (0.46 to 0.7)                    |
| Male, n (%)                                         | 986 (65.34)           | 215 (62.14)            | 3.21 (–2.62 to 9.03)                  |
| Mean BMI (SD), kg/m²                                 | 26.74 (4.38)          | 25.79 (4.53)           | 0.21 (0.10 to 0.33)                   |
| Retransplant, n (%)                                  | 168 (11.13)           | 47 (13.58)             | –2.45 (–6.57 to 1.67)                 |
| Mean most recent estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration) (SD), ml/min/1.73 m² | 49.2 (21)             | 48.6 (20.4)            | 1.8 (–4.8 to 9)                       |
| Mean time from transplant (SD), d                   | 8.45 (6.87)           | 8.53 (6.91)            | –0.01 (–0.13 to 0.1)                  |
| Mean follow-up time (SD), d                         | 46.17 (26.76)         | 72.81 (29.78)          | –0.98 (–1.1 to –0.86)                 |
| Vaccination status against influenza in 2019, n (%)† | 323 (47.71)           | 33 (24.63)             | 2.44 (1.34 to 3.54)                   |
| University/college degree, n (%)                    | 192 (12.72)           | 31 (8.96)              | 3.76 (0.14 to 7.39)                   |
| Urban place of residence, n (%)                     | 360 (23.86)           | 75 (21.68)             | 2.18 (–5.3 to 4.3)                    |
| Tacrolimus in maintenance immunosuppression, n (%)  | 1249 (82.77)          | 287 (82.95)            | –0.18 (–4.75 to 4.44)                 |
| Cyclosporine A in maintenance immunosuppression, n (%) | 152 (10.07)           | 31 (8.96)              | 1.11 (–2.44 to 4.64)                  |
| Prednisone in maintenance immunosuppression, n (%)  | 1336 (88.54)          | 301 (86.99)            | 1.55 (–2.53 to 5.61)                  |
| Mycophenolate in maintenance immunosuppression, n (%) | 1228 (81.38)          | 275 (79.48)            | 1.91 (–2.97 to 6.76)                  |
| Mechanistic target of rapamycin inhibitor in maintenance immunosuppression, n (%) | 115 (7.62)            | 20 (5.78)              | 1.84 (–1.14 to 4.82)                  |
| Belatacept in maintenance immunosuppression, n (%)   | 9 (0.6)               | 2 (0.58)               | 0.02 (–0.89 to 0.93)                  |
| SARS-CoV-2 vaccine, n (%)                           | 1274 (84.43)          | –                     | –                                     |
| mRNA-1273                                            | 235 (15.57)           | –                     | –                                     |

BMI = body mass index; KTR = kidney transplant recipient.

* Standardized mean differences are reported specifically as Cohen d with pooled SD for continuous variables and proportion differences for binary variables.

† Data missing for 832 (55.1%) and 212 (61.3%) patients in the vaccinated and unvaccinated groups, respectively.
seen early on, and at the time, the proportion of vaccinated participants was low. Over time, the proportion of vaccinated participants was increasing, whereas the baseline risk for infection was decreasing. Thus, the final rate of SARS-CoV-2 infections in the unvaccinated cohort at the end of the study was unusually high. The study captures a public health crisis of a catastrophic scale and therefore provides unique data to evaluate SARS-CoV-2 mRNA vaccines in a real-world setting and with an extremely high risk for infection.

Testing for COVID-19 was covered by national health insurance; therefore, participants could be tested without hindrance. However, we acknowledge the KTR group may have had a slightly higher diagnostic rate. Our transplant center used an attentive system of KTR follow-up and support during the COVID-19 pandemic. Each KTR at our center has the means to directly contact their physician or transplant coordinator at any time. To boost early case detection, KTRs were repeatedly advised and educated to have a PCR test done if presenting any signs of COVID-19 illness. During the third wave of the pandemic, the government introduced mandatory regular testing for COVID-19 for employees, thereby increasing the detection rate in asymptomatic participants.

**Incidence Rate Ratios and Poisson Regression Models**

The unadjusted incidence rate ratio (IRR) is a ratio of the incidence rate in the vaccinated group and the unvaccinated group. The incidence rate is a ratio of the number of events and the days at risk for either the vaccinated or unvaccinated group.

Multivariable Poisson regression was used to derive the adjusted IRR. The models were adjusted for sex, BMI at the last check-up before study initiation, college or university degree, days from transplant, immunosuppression, and rural or urban place of residence. Because there are strong temporal trends in terms of the risk for infection (Figure 2) during the study follow-up, further adjustment was done. The model was adjusted to baseline risk by using a categorical covariate representing 1 of the 3 months of the study period in which the patient’s follow-up started. No variable for which we adjusted the models had missing values.

The multivariable Poisson regression model was not adjusted to age because of multicollinearity between calendar time, vaccination status, and age. We computed the variance inflation factor for the covariates in the adjusted model, and we obtained 2.02 for vaccination, 1.68 for age, and 1.45 for calendar interval 2. We decided on variance inflation factor cutoff 2 for vaccination. We cannot remove vaccination and calendar interval covariates from the model (otherwise we would have no treatment effect or adjustment to background risk); therefore, we removed the age covariate to avoid multicollinearity. In the modified model, the variance inflation factor decreased to 1.49 for vaccination and 1.39 for interval 2. For a detailed description of the regression model, see the Appendix (available at Annals.org).

**Statistical Analysis**

Continuous variables are expressed as mean (SD). Categorical variables are expressed as number (percentage) of participants within each group. The intergroup differences are reported as standardized mean differences (that is, Cohen d with pooled SD) for continuous variables and proportion differences for binary variables (both measures are reported along with their 95% CIs).
Apart from the adjusted IRR, we also report marginally standardized incidence rates (24). To compute the marginally standardized incidence rate for the unvaccinated group, we predicted the response of each observation using the fitted model while assuming that each observation belongs to the unvaccinated group. Analogously, the marginally standardized incidence rate for the vaccinated group was computed by predicting the response of each observation using the fitted model while assuming that each observation belongs to the vaccinated group. Having predicted responses for each observation, we sum up these responses and divide them by the total follow-up time of all of the observations. The CIs for the marginally standardized incidence rates were computed using the bootstrap method (R package boot [R Foundation for Statistical Computing], type percentile, 2000 replicates). The statistical analysis was done in R, version 4.1.1 (R Foundation for Statistical Computing).

Role of the Funding Source
The funding source had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

RESULTS
Participants
A total of 2479 KTRs were considered for inclusion. After the exclusion of KTRs previously infected with SARS-CoV-2 and those vaccinated with vector-based vaccines (ChAdOx1 nCoV-19 and Ad26.COV2.S), 2101 KTRs were included in the analysis. Of those, 1509 reached full vaccination status, 346 were not fully vaccinated until the end of the study period, and 246 did not have complete vaccination (Figure 1 and Table 1). No patient was lost to follow-up, 11 patients during the follow-up period were censored (9 patients died from causes unrelated to COVID-19, and 2 patients had graft failure). The fully vaccinated and unvaccinated groups did not vary in basic characteristics, apart from age, length of follow-up in the study, and, interestingly, in the rate of vaccination against influenza in 2019.

The cumulative proportion of fully vaccinated KTRs during the study period is shown in Figure 2.

Incidence Rates and IRR in the KTR Cohort
Infection with SARS-CoV-2 was reported in 33 vaccinated and 79 unvaccinated KTRs. The incidence rate in the vaccinated group was 0.474 per 1000 person-days (33 cases in 69 672 days at risk), and the incidence rate in the unvaccinated group was 1.370 per 1000 person-days (79 cases in 57 658 days at risk). Thus, the unadjusted IRR was 0.346 (95% CI, 0.227 to 0.514). Incidence of COVID-19 during the study period for the unvaccinated and vaccinated KTRs, along with the general population, are shown in Figure 3.

Furthermore, the adjusted IRR was calculated (using a multivariable Poisson regression model) for KTR sex, BMI, days from transplant, maintenance immunosuppressive regimen, university or college degree, place of residence (rural or urban), and calendar time. The adjusted IRR was 0.544 (CI, 0.324 to 0.876). The marginally standardized incidence rate for the vaccinated group was 0.06 (CI, 0.037 to 0.085), whereas the rate for the unvaccinated...
DISCUSSION

The clinical outcomes are summarized in Table 2. Eighteen KTRs died of COVID-19-related causes during the study period—10 unvaccinated and 8 vaccinated. Vaccinated KTRs who were infected (median age, 71 vs. 50 years) and who died (median age, 72.5 vs. 61 years) were older than unvaccinated KTRs. Granular description of these cases is given in Appendix Table 2 (available at Annals.org).

The estimates of real-world vaccine effectiveness in the general population had also been reported. For instance, Angel and colleagues (26) reported unadjusted IRR (0.03 [CI, 0.01 to 0.06]) in health care workers. However, this report, like many others, uses methods that may at times misrepresent vaccine effectiveness. The problem stems from the days-at-risk calculation method when the vaccinated group is followed up only from the moment of reaching full vaccination status, whereas the unvaccinated group’s follow-up starts from an arbitrarily decided point in time. This produces a 2-fold problem. First, the follow-up time of the vaccinated participants is then inherently shorter, and second, because of the strong temporal trends in COVID-19 outbreaks, the risk for infection may vary during the study period. Therefore, even though the days at risk for 2 patient groups could be the same, the risk for being infected during that time could be substantially different, which was the case in our study. These issues have been addressed by several statistical approaches, such as calendar time adjustments in a multivariable Poisson regression model.

It should be emphasized that this report was possible only because of several factors. First, the extremely high viral load in the population and resulting incidence of new cases during the second and third waves in the first half of 2021, combined with a relatively fast SARS-CoV-2 vaccine rollout in the KTR population, resulting in a unique combination of many events in both vaccinated and unvaccinated control participants during a relatively narrow time frame of the study. Second, the National Registry for Infectious Diseases provided a reliable, nationwide source of data on the KTR population followed at IKEM.

The strengths of this study are the use of reliable data from the central nationwide registry (22), the large cohort in a high-volume transplant center, and the high rates of COVID-19 cases due to the severe wave of COVID-19 in the spring of 2021. The limitations of this study are the retrospective observational design and uneven follow-up. The observational design is especially limiting because of the strong temporal trends in terms of the changing risk for baseline infection, and no statistical adjustment can fully substitute a well-designed randomized controlled trial in this scenario. However, because KTRs are at such high risk for a serious course of the disease, it may not be ethically feasible to deny them any kind of protection. Observational group was 0.11 (CI, 0.083 to 0.143). The detailed model is shown in Appendix Table 1 (available at Annals.org).

Clinical Characteristics of the Infections in the KTR Cohorts

To explore possible effectiveness of vaccination against COVID-19 severity, we have analyzed clinical data from vaccinated and unvaccinated patients infected with SARS-CoV-2. The clinical outcomes are summarized in Table 2.

The strengths of this study are the use of reliable data from the central nationwide registry (22), the large cohort in a high-volume transplant center, and the high rates of COVID-19 cases due to the severe wave of COVID-19 in the spring of 2021. The limitations of this study are the retrospective observational design and uneven follow-up. The observational design is especially limiting because of the strong temporal trends in terms of the changing risk for baseline infection, and no statistical adjustment can fully substitute a well-designed randomized controlled trial in this scenario. However, because KTRs are at such high risk for a serious course of the disease, it may not be ethically feasible to deny them any kind of protection. Observational group was 0.11 (CI, 0.083 to 0.143). The detailed model is shown in Appendix Table 1 (available at Annals.org).

Clinical Characteristics of the Infections in the KTR Cohorts

To explore possible effectiveness of vaccination against COVID-19 severity, we have analyzed clinical data from vaccinated and unvaccinated patients infected with SARS-CoV-2. The clinical outcomes are summarized in Table 2. Eighteen KTRs died of COVID-19-related causes during the study period—10 unvaccinated and 8 vaccinated. Vaccinated KTRs who were infected (median age, 71 vs. 50 years) and who died (median age, 72.5 vs. 61 years) were older than unvaccinated KTRs. Granular description of these cases is given in Appendix Table 2 (available at Annals.org).

Despite the rapid publication activity of COVID-19-related studies and reports, evidence lags behind the urgency for decision makers. Both the humoral and cellular immune responses have been reported to be substantially impaired in KTRs (7–9), and the current expert boards’ recommendations about additional booster doses in solid organ transplant recipients are based mainly on these observations (17, 18). It is, however, the clinical vaccine effectiveness that matters to patients, society, and decision makers.

Our study points toward an association between 2 doses of SARS-CoV-2 mRNA vaccines and a lower risk for COVID-19 illness in KTRs. Data of the general population obtained from the National Registry for Infectious Diseases registry, however, show that infection risk was one order of magnitude higher for KTRs than the general population (unadjusted IRR, 0.036 from January to June 2021; data not shown).

To date, only a handful of studies reporting the real-world effectiveness of SARS-CoV-2 vaccines in solid organ recipients with conflicting results were published. In a study by Aslam and colleagues (15), clinical effectiveness with almost 80% reduction in the incidence of symptomatic COVID-19 among vaccinated solid organ recipients was seen in a U.S. cohort between 1 January and 2 June 2021. Kidney transplant recipients represented 44.5% of the cohort, and almost 70% were vaccinated with mRNA vaccines. On the other hand, a recent study by Callaghan and colleagues (14) showed no effectiveness against SARS-CoV-2 infection in a British cohort from 1 June to 31 August 2021, although SARS-CoV-2 vaccination was associated with reduced COVID-19-related death. The conflicting outcomes could be at least partly attributed to the differences between the studies—for example, during Callaghan and colleagues’ study, the Delta variant was the dominant virus variant as opposed to the Alpha variant being the dominant variant during Aslam and colleagues’ study and our study. Because SARS-CoV-2 vaccination is less effective against the Delta variant than it is against the Alpha variant in the general population (25), one may speculate that perhaps 2-dose vaccination in solid organ recipients reached its limits with this virus variant. Another study by Qin and colleagues (13) showed that the risk for breakthrough infections is higher in solid organ recipients than in the general population, but a missing comparison to unvaccinated persons limits the interpretation of vaccine effectiveness. These findings are in line with the findings from our study.

The estimates of real-world vaccine effectiveness in the general population had also been reported. For instance, Angel and colleagues (26) reported unadjusted IRR (0.03 [CI, 0.01 to 0.06]) in health care workers. However, this report, like many others, uses methods that may at times misrepresent vaccine effectiveness. The problem stems from the days-at-risk calculation method when the vaccinated group is followed up only from the moment of reaching full vaccination status, whereas the unvaccinated group’s follow-up starts from an arbitrarily decided point in time. This produces a 2-fold problem. First, the follow-up time of the vaccinated participants is then inherently shorter, and second, because of the strong temporal trends in COVID-19 outbreaks, the risk for infection may vary during the study period. Therefore, even though the days at risk for 2 patient groups could be the same, the risk for being infected during that time could be substantially different, which was the case in our study. These issues have been addressed by several statistical approaches, such as calendar time adjustments in a multivariable Poisson regression model.

It should be emphasized that this report was possible only because of several factors. First, the extremely high viral load in the population and resulting incidence of new cases during the second and third waves in the first half of 2021, combined with a relatively fast SARS-CoV-2 vaccine rollout in the KTR population, resulting in a unique combination of many events in both vaccinated and unvaccinated control participants during a relatively narrow time frame of the study. Second, the National Registry for Infectious Diseases provided a reliable, nationwide source of data on the KTR population followed at IKEM.

The strengths of this study are the use of reliable data from the central nationwide registry (22), the large cohort in a high-volume transplant center, and the high rates of COVID-19 cases due to the severe wave of COVID-19 in the spring of 2021. The limitations of this study are the retrospective observational design and uneven follow-up. The observational design is especially limiting because of the strong temporal trends in terms of the changing risk for baseline infection, and no statistical adjustment can fully substitute a well-designed randomized controlled trial in this scenario. However, because KTRs are at such high risk for a serious course of the disease, it may not be ethically feasible to deny them any kind of protection. Observational...
data may therefore be the only alternative to estimate the vaccination effectiveness. The uneven follow-up is largely corrected by the statistical method and follow-up time definition. Furthermore, different behavioral patterns that could be assumed in persons who decided either for or against vaccination may also be a source of bias.

It is important to note that the available data on disease severity in breakthrough infections and deaths must be interpreted cautiously. The inherent differences between the groups, especially in terms of age, hinder direct comparison, and the low number of observed events precludes multivariable modeling and further adjustments.

It is also necessary to stress that these data are pertinent only for the study period, which was done during a time when the Alpha variant was predominant. The change of the baseline setting, mainly due to the emerging variants of concern, can lead to further attenuation of the real-world effectiveness (27).

In conclusion, the association between 2 doses of mRNA SARS-CoV-2 vaccines and lowered risk for infection shown in our study provides much needed real-world evidence. However, despite the effectiveness in KTRs, there were still breakthrough infections, and indirect comparisons suggest lower effectiveness compared with the general population. Thus, we believe that the current recommendations for additional booster doses based on laboratory immune-monitoring studies are also supported by our clinical report. Kidney transplant recipients should continue to be prioritized for booster doses in vaccination programs.

From Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (I.Z., V.P., M.M., O.V.); Information Technology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (I.M.); and Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic (L.D.).

Acknowledgment: The authors thank Mrs. Adela Sucha for invaluable help with clinical data reporting and Petr Raska, MSc, and Michal Hojny, PharmD, for organization of the vaccination campaign at IKEM.

Financial Support: The IKEM is supported by the Ministry of Health of the Czech Republic by its conceptual development of research organizations grant (IKEM, IN 00023001) and NU22-C-126.

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-2973.

Reproducible Research Statement: Study protocol, statistical code, and data set: Available from Dr. Vikicky on reasonable request (e-mail, ondrej.vikicky@ikem.cz).

Corresponding Author: Ondrej Vikicky, MD, PhD, Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21, Prague, Czech Republic; e-mail, ondrej.vikicky@ikem.cz.

Author contributions are available at Annals.org.

References

1. Phanish M, Ster IC, Ghazanfar A, et al. Systematic review and meta-analysis of COVID-19 and kidney transplant recipients, the South West London Kidney Transplant Network experience. Kidney Int Rep. 2021;6:574-585. [PMID: 33363263] doi:10.1016/j.ekir.2020.12.013

2. Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98:1540-1548. [PMID: 32979369] doi:10.1016/j.kint.2020.09.006

3. Hilbrands LB, Duivenvoorden R, Vart P, et al; ERACODA Collaborators. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35:1973-1983. [PMID: 33151337] doi:10.1093/ndt/gfaa261

4. Caillard S, Anglicheau D, Matignon M, et al; French SOT COVID Registry. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int. 2020;98:1549-1558. [PMID: 32853631] doi:10.1016/j.kint.2020.08.005

5. Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-416. [PMID: 33378609] doi:10.1056/NEJMoa2035389

6. Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-2615. [PMID: 33031246] doi:10.1056/NEJMoa2034577

7. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21:2719-2726. [PMID: 33866672] doi:10.1111/ajt.16615

8. Marion O, Del Bello A, Abravanel F, et al. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants [Letter]. Ann Intern Med. 2021;174:1336-1338. [PMID: 34029487] doi:10.7326/M21-1341

9. Bertrand D, Hamzaoui M, Lémée V, et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021;32:2147-2152. [PMID: 34112706] doi:10.1681/ASN.2021040480

10. Smith KG, Isbel NM, Catton MG, et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant. 1998;13:160-4. [PMID: 9481733]

11. Sanchez-Frutuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectiveness in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation. 2000;69:436-439. [PMID: 10706057]

12. Dendle C, Stuart RL, Polkinghome KR, et al. Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis. 2018;20:e12866. [PMID: 29512234] doi:10.1111/tid.12866

13. Qin CX, Moore LW, Anjan S, et al. Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients [Letter]. Transplantation. 2021;105:e265-e266. [PMID: 34310531] doi:10.1097/TP.0000000000003907

14. Callaghan CJ, Mumford L, Curtis RMK, et al; NHSBT Organ and Tissue Donation and Transplantation Clinical Team. Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients. Transplantation. 2022;106:436-446. [PMID: 34982758] doi:10.1097/TP.0000000000004059

15. Aslam S, Adler E, Mekeel K, et al. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transplant Infect Dis. 2021;23:e13705. [PMID: 34324256] doi:10.1111/tid.13705

16. Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021. [PMID: 34297036] doi:10.1001/jama.2021.12339

Annals.org
Beyond the Guidelines

Beyond the Guidelines is a multimedia feature based on clinical conferences at Beth Israel Deaconess Medical Center. In each feature, experts discuss the case of a patient whose care “falls between the cracks” in available evidence and for whom the optimal clinical management is unclear. Clinical experts provide opinions and comment on how they would approach the patient’s care. Videos of the patient’s story and the conference accompany the article, along with a CME/MOC activity offering AMA PRA Category 1 Credit(s)™.

For more information, visit Annals.org/GrandRounds.
**Author Contributions:** Conception and design: I. Modos, V. Petr, O. Viklicky, I. Zahradka. Analysis and interpretation of the data: L. Dusek, M. Magicova, I. Modos, V. Petr, O. Viklicky, I. Zahradka. Drafting of the article: M. Magicova, V. Petr, O. Viklicky, I. Zahradka. Critical revision of the article for important intellectual content: M. Magicova, V. Petr, O. Viklicky, I. Zahradka. Final approval of the article: L. Dusek, M. Magicova, I. Modos, V. Petr, O. Viklicky, I. Zahradka. Statistical expertise: L. Dusek, I. Modos. Obtaining of funding: O. Viklicky. Collection and assembly of data: M. Magicova, I. Modos, V. Petr, I. Zahradka.

**APPENDIX: Statistical Appendix—Detailed Description of the Poisson Multivariable Regression Model**

The Poisson regression was fitted using the following covariates:

- Vaccination status (binary, 1 = vaccinated),
- Sex (binary, 1 = man),
- University/college degree (binary, 1 = yes),
- Urban place of residence (binary, 1 = yes),
- BMI (continuous),
- Time from kidney transplantation (continuous, in years),
- Immunosuppression: Tacrolimus, Cyclosporine A, Prednisone, Mycophenolate, mTOR inhibitor, Belatacept (all binary variables, 1 = yes),
- And month (categorical, see below for details).

The offset is a logarithm of the follow-up days and the response variable is binary with 1 representing that the event occurred. The data are provided at individual level.

The model was adjusted to baseline risk by using a categorical covariate month representing the time interval, in which the patient’s follow-up started. The time intervals are: 17 February to 16 March 2021 (reference interval), 17 March to 16 April 2021, and 17 April to 16 May 2021. Please note that vaccinated patients that contribute both to vaccinated and unvaccinated days at risk are represented twice in the data with different value of month covariate.

The fitting was done in R language using glm function and family = "poisson."

**Appendix Table 1. Adjusted IRR With Poisson Regression Modeling**

| Covariate                                           | Adjusted IRR (95% CI) |
|-----------------------------------------------------|-----------------------|
| Vaccinated                                          | 0.544 (0.324–0.876)   |
| Male                                                | 0.831 (0.569–1.225)   |
| University/college degrees                          | 1.216 (0.625–2.162)   |
| Urban place of residence                            | 0.887 (0.538–1.402)   |
| BMI                                                 | 0.996 (0.95–1.039)    |
| Years from kidney transplant                        | 0.98 (0.945–1.014)    |
| Tacrolimus in maintenance immunosuppression         | 1.889 (0.593–8.604)   |
| Cyclosporine A in maintenance immunosuppression     | 2.444 (0.482–11.77)   |
| Prednisone in maintenance immunosuppression         | 1.541 (0.747–3.610)   |
| Mycophenolate in maintenance immunosuppression      | 1.1 (0.644–1.997)     |
| Mechanistic target of rapamycin inhibitor in         | 0.75 (0.204–2.127)    |
| maintenance immunosuppression                        |                       |
| Belatacept in maintenance immunosuppression         | 3.473 (0.162–30.82)   |
| Calendar time adjustment                            |                       |
| 17 February–16 March                                 | Reference             |
| 17 March–16 April                                   | 0.409 (0.189–0.834)   |
| 17 April–17 May                                     | 0.385 (0.021–1.845)   |

BMI = body mass index; IRR = incidence rate ratio; KTR = kidney transplant recipient.

* There were 33 cases of SARS-CoV-2 infection detected among vaccinated KTRs and 79 cases among unvaccinated KTRs during the study period.
## Appendix Table 2: COVID-19-Related Deaths in KTRs

| Case Number | Vaccination Status | Sex | Age, y | Time From Transplant, mo | BMI, kg/m² | Diabetes Mellitus | Retransplant Human Leukocyte Antigen Mismatch, % | Maximum Pretransplant Panel-Reactive Antibodies, n | eGFR, ml/min/1.73 m² | Maintenance Immunosuppression | Induction Rejection Treatment in the Past Year | Cause of Death |
|-------------|--------------------|-----|--------|---------------------------|------------|------------------|-----------------------------------------------|-----------------------------------------------|------------------|----------------------------------------|-----------------------------------------------|----------------|
| 1           | Vaccinated         | Male | 70     | 202                       | 26.2       | No               | No                                           | 4                                                             | 93.6             | CyA + MMF + CS                      | None                         | No COVID-19-related pneumonia + generalized cancer |
| 2           | Vaccinated         | Female | 78     | 182                       | 20.2       | No               | No                                           | 3                                                             | 0               | CyA + MMF                           | None                         | No COVID-19-related pneumonia |
| 3           | Vaccinated         | Male | 82     | 143                       | 25.8       | No               | No                                           | 3                                                             | 0               | CyA + CS                            | None                         | No COVID-19-related pneumonia + terminal dementia |
| 4           | Vaccinated         | Female | 71     | 96                        | 30.3       | Yes              | No                                           | 2                                                             | 2               | TAC + CS                            | T-cell depleting             | No COVID-19-related pneumonia |
| 5           | Vaccinated         | Male | 71     | 87                        | 27.3       | Yes              | No                                           | 3                                                             | 16              | CyA + MMF + CS                      | T-cell depleting             | No COVID-19-related pneumonia |
| 6           | Vaccinated         | Male | 74     | 43                        | 26         | Yes              | No                                           | 2                                                             | 48              | TAC + MMF + CS                      | T-cell depleting             | No COVID-19-related pneumonia + bilateral heart failure |
| 7           | Vaccinated         | Male | 70     | 49                        | 32.5       | No               | No                                           | 3                                                             | 2               | TAC + MMF + CS                      | Basiliximab                 | No COVID-19-related pneumonia |
| 8           | Vaccinated         | Female | 74     | 23                        | 30.1       | Yes              | No                                           | 5                                                             | 56              | TAC + MMF + CS                      | Basiliximab                 | No COVID-19-related pneumonia |
| 9           | Unvaccinated       | Male | 54     | 4                         | 17.6       | No               | No                                           | 4                                                             | 6               | CyA + MMF + CS                      | Basiliximab                 | No COVID-19-related pneumonia |
| 10          | Unvaccinated       | Female | 54     | 128                       | 41         | Yes              | No                                           | 3                                                             | 78              | TAC + MMF + CS                      | T-cell depleting             | No COVID-19-related pneumonia |
| 11          | Unvaccinated       | Male | 62     | 123                       | 21.7       | Yes              | No                                           | 5                                                             | 0               | TAC + MMF + CS                      | Basiliximab                 | No COVID-19-related pneumonia |
| 12          | Unvaccinated       | Male | 72     | 89                        | 35.8       | Yes              | No                                           | 2                                                             | 4               | CyA + MMF + CS                      | Basiliximab                 | No COVID-19 illness + terminal dementia |
| 13          | Unvaccinated       | Male | 69     | 98                        | 33.2       | Yes              | No                                           | 1                                                             | 0               | TAC + CS                            | T-cell depleting             | No COVID-19-related pneumonia |
| 14          | Unvaccinated       | Male | 69     | 74                        | 29.7       | No               | No                                           | 2                                                             | 0               | TAC + MMF + CS                      | T-cell depleting             | No COVID-19-related pneumonia |
| 15          | Unvaccinated       | Male | 60     | 39                        | 45.4       | No               | No                                           | 5                                                             | 6               | TAC + MMF + CS                      | T-cell depleting             | No COVID-19-related pneumonia + bilateral heart failure |
| 16          | Unvaccinated       | Male | 68     | 39                        | 30.9       | Yes              | No                                           | 4                                                             | 1               | TAC + CS                            | T-cell depleting             | No COVID-19-related pneumonia |
| 17          | Unvaccinated       | Male | 46     | 45                        | 35.1       | No               | No                                           | 3                                                             | 0               | TAC + MMF + CS                      | Basiliximab                 | No COVID-19-related pneumonia |
| 18          | Unvaccinated       | Male | 70     | 37                        | 23.7       | No               | No                                           | 3                                                             | 0               | TAC + MMF + CS                      | T-cell depleting             | No COVID-19-related pneumonia |

BMI = body mass index; CyA = cyclosporine A; CS = corticosteroids; eGFR = estimated glomerular filtration rate with Chronic Kidney Disease Epidemiology Collaboration equation; KTR = kidney transplant recipient; MMF = mycophenolate mofetil or mycophenolic acid; TAC = tacrolimus.